Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00399685 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction - Oral Contraceptive
A Phase 1 study of HIV Infections, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT00399685: Completed Phase 1 study of HIV Infections, sponsored by Bristol-Myers Squibb.
NCT00399685 is a Phase 1 study of HIV Infections that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 28 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00399685, a Phase 1 study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to administer a combined oral contraceptive containing ethinyl estradiol and norgestimate with the HIV treatment of efavirenz to healthy females in order to assess if the concentrations of the oral contraceptives change. The safety of this treatment regimen will also be studied.
Conditions Studied
Interventions
- DRUG Ortho Tri-Cyclen LO
- DRUG Ortho Cyclen
- DRUG Ortho Cyclen + Efavirenz
Study Locations (2)
California
- Covance Clinical Research Unit San Diego - San Diego
Washington
- Northwest Kinetics - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
What the finished NCT00399685 record still lists
NCT00399685 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Ortho Tri-Cyclen LO is the first listed.
NCT00399685 reports a single indexed study location in California, Washington.
Frequently Asked Questions
What is clinical trial NCT00399685 about?
NCT00399685 is a clinical study titled "Drug Interaction - Oral Contraceptive". The purpose of this study is to administer a combined oral contraceptive containing ethinyl estradiol and norgestimate with the HIV treatment of efavirenz to healthy females in order to assess if the concentrations of the oral contraceptives change. The safety of this treatment regimen will also be ...
What is the current status of trial NCT00399685?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2006-12. Estimated completion is 2007-08.
What conditions does trial NCT00399685 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00399685?
The interventions under investigation include: Ortho Tri-Cyclen LO (DRUG), Ortho Cyclen (DRUG), Ortho Cyclen + Efavirenz (DRUG).
Who is sponsoring clinical trial NCT00399685?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00399685 being conducted?
This trial has 2 study locations across California, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00399685's enrollment target sits among peer trials
28 447th of 542 higher than 94 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia